IL2 and non-small cell lung carcinoma: NSCLC patients show heterogeneous IL-2 responses with two distinct patterns: some patients begin with elevated baseline levels (75–80 pg/mL) that decrease over the treatment period, while others maintain consistently low levels throughout (10–20 pg/mL).